Overexpression of NDRG1 leads to poor prognosis in hepatocellular carcinoma through mediating immune infiltration and EMT. 2024

Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
Department of Pathology, Tianjin Medical University, Tianjin 300070, China.

BACKGROUND NDRG1, the first member of the NDRG family, is a multifunctional protein associated with carcinogenesis. Its function in human cancer is currently poorly understood. The aim of this study was to explore the importance of NDRG1 in tumor immune cell infiltration and epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. METHODS NDRG1 expression in various cancers was analyzed using TIMER 2.0, the Human Protein Atlas (HPA), UALCAN and PrognoScan. Wound healing, Transwell, MTT and colony formation assays were performed to confirm the effects of NDRG1 on the metastasis and proliferation of HCC cells. Western blotting was used to study the effect of NDRG1 on the expression of EMT-related proteins. Signaling networks were constructed using LinkedOmics and Metascape. TIMER2.0 and TISIDB were used for comprehensive analysis of tumor-infiltrating immune cells and tumor-infiltrating lymphocytes (TILs). RESULTS NDRG1 expression was higher in HCC tissue than in normal liver tissue at both the mRNA and protein levels. Overexpression of NDRG1 is associated with poor prognosis in HCC patients. Genomic analysis suggests that NDRG1 promoter hypermethylation leads to enhanced transcription, which may be one mechanism for NDRG1 upregulation in HCC. The overexpression of NDRG1 promotes the invasion, migration, and proliferation of HCC cells and induces the expression of EMT-related proteins. Immunoinfiltration analysis suggests that NDRG1 is involved in the recruitment of immune cells. CONCLUSIONS The present study showed that NDRG1 may induce metastasis and invasion through EMT and immune cell infiltration. NDRG1 could be used as a biomarker for the diagnosis and prognosis of HCC and could be a potential therapeutic target in HCC.

UI MeSH Term Description Entries

Related Publications

Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
May 2013, Oncology reports,
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
January 2007, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
September 2023, Discover. Oncology,
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
January 2024, Aging,
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
January 2020, OncoTargets and therapy,
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
July 2023, Cancer cell international,
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
December 2012, Hepatology (Baltimore, Md.),
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
April 2023, Scientific reports,
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
January 2022, Frontiers in genetics,
Xiao Wang, and Ran Sun, and Na Che, and Danfang Zhang, and Yanlei Li, and Nan Zhao
January 2023, International journal of molecular sciences,
Copied contents to your clipboard!